Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency.
The influence of pentoxifylline (11-18 mg/kg orally, Trental 400) on impaired hemorheologic conditions has been investigated in a total of 73 patients with CVI. Throughout a treatment period of 4 weeks, there was a significant improvement in red cell behavior and a significant inhibition of increased platelet aggregation; moreover, a fall in plasma fibrinogen and of blood viscosity has also been observed.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D001809:Blood Viscosity; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D004837:Epinephrine / Q000037:antagonists & inhibitors; D004912:Erythrocytes / Q000502:physiology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D012212:Rheology; D013805:Theobromine / Q000031:analogs & derivatives*
D000244:Adenosine Diphosphate; D005340:Fibrinogen; D013805:Theobromine; D010431:Pentoxifylline; D004837:Epinephrine